Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a focus on marine economy and health products as key growth drivers [2] Financial Performance - The company achieved operating revenue of 417 million yuan, a year-on-year increase of 17.11% [2] - Net profit attributable to shareholders reached 112 million yuan, reflecting a 47.03% increase compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 111 million yuan, up 54.21% year-on-year [2] Business Strategy - Chengyi Pharmaceutical is committed to the dual-driven strategy of pharmaceuticals and health products, aligning with national initiatives to develop the marine economy and marine biomedicine [2] - In the pharmaceutical sector, the company focuses on a full industry chain approach, increasing R&D investment to enhance competitive advantages in clinical treatment areas such as bone and joint, cardiovascular, anti-infection, and nervous system [2] Product Development - The company prioritized key profitable products for consistency evaluation and new product development, successfully passing consistency evaluation for two specifications of sodium cytidine injection [2] - New products such as mercaptopurine tablets have been approved, and the raw material for dobutamine hydrochloride has been filed successfully [2] - As of the date of the interim report, the company has obtained a drug registration certificate for palivizumab injection [2] Market Focus - In the health product sector, the company strategically focuses on marine biomedicine and the silver economy, seizing opportunities from consumption upgrades and increased health awareness [2]

Group 1 - The company achieved a revenue of 417 million yuan in the first half of 2025, representing a year-on-year growth of 17.11% [1] - The net profit attributable to shareholders reached 112 million yuan, with a year-on-year increase of 47.03% [1] - The company is focusing on deepening its existing product lines and expanding its marketing network, enhancing collaboration with distributors and agents [1] Group 2 - The main product, Glucosamine Hydrochloride Capsules, has secured bids in most provinces through specialized academic promotion and commercial partnerships [1] - The company is strengthening management of distributors and tracking the flow of products to medical institutions and OTC, enhancing market risk control for sustainable sales growth [1] - The company is building a marketing center in Shanghai Hongqiao Business District and actively recruiting marketing talent to create a high-quality team [1] Group 3 - The company emphasizes "quality first" in production management, implementing comprehensive quality management from raw material procurement to transportation [2] - The company has strengthened audits and on-site management of raw material suppliers, advancing quality risk management [2] - The company received the "Wenzhou Green Factory" certification in 2024 for its safe, environmentally friendly, and efficient production [2] Group 4 - The company is focusing on key advantageous products in its R&D efforts, progressing with consistency evaluations and new product development [2] - The Sodium Cytidine Injection successfully passed consistency evaluation during the reporting period [2] - The company has received registration approval for the Palivizumab Injection prior to the report disclosure [3]

Core Viewpoint - Chengyi Pharmaceutical has received approval for its Palivizumab injection, marking a significant milestone in its drug development efforts and expanding its product line in the influenza treatment market [1][2] Group 1: Drug Approval and Market Position - The Palivizumab injection has been approved as a Class 3 chemical drug for the treatment of influenza A or B [1] - In 2023, the total sales of the four main influenza treatment drugs in the domestic market reached 11.405 billion yuan, with Oseltamivir holding the majority market share [1] - Palivizumab is recognized as the first innovative Class 1 anti-influenza drug approved in China, recommended in various influenza treatment guidelines [1] Group 2: Product Line Expansion and Financial Performance - Over the past year, Chengyi Pharmaceutical has launched multiple products in the formulation sector, continuously expanding its product line [2] - The company expects a net profit attributable to shareholders of 107 million to 119 million yuan for the first half of 2025, representing a year-on-year growth of 40% to 55%, primarily driven by the sales growth of joint-related drugs [2] - The company is also advancing its "Two Strong One Big Project" initiative in marine biomedicine, with a large-scale EPA fish oil production project underway, which is expected to become a core revenue driver alongside joint-related drugs [2]

北京星昊医药股份有限公司 北京市北京经济技术开发区中和街 18 号 证券简称： 星昊医药 证券代码： 430017 北京星昊医药股份有限公司招股说明书 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证 券交易所主要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风 险高等特点，投资者面临较大的市场风险。投资者应充分了解北京证券交易所市场的 投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） 新疆乌鲁木齐市高新区(新市区)北京南路 358 号大成国际大厦 20 楼 2004 室 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表 明其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不 表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或 者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资 风险。 1-1-2 声明 ...

证券简称： 星昊医药 证券代码： 430017 北京市北京经济技术开发区中和街 18 号 北京星昊医药股份有限公司 北京星昊医药股份有限公司招股说明书（注册稿） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证 券交易所主要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风 险高等特点，投资者面临较大的市场风险。投资者应充分了解北京证券交易所市场的 投资风险及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） 新疆乌鲁木齐市高新区(新市区)北京南路 358 号大成国际大厦 20 楼 2004 室 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表 明其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不 表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或 者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资 风险。 1-1- ...

北京市北京经济技术开发区中和街 18 号 北京星昊医药股份有限公司 北京星昊医药股份有限公司招股说明书（注册稿） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构（主承销商） 申万宏源证券承销保荐有限责任公司 新疆乌鲁木齐市高新区(新市区)北京南路 358 号大成国际大厦 20 楼 2004 室 证券简称： 星昊医药 证券代码： 430017 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行 ...